Abstract
Immune checkpoint inhibitors have demonstrated remarkable benefits in cancer patients. However, concern regarding toxicity in the setting of stereotactic radiosurgery (SRS) is often raised. In this study, we characterize radiation necrosis (RN) following immunotherapy and SRS. Melanoma patients treated with SRS and anti-CTLA-4 and/or anti-PD-1 at our institution from January 2006 to December 2015 were retrospectively reviewed. Overall survival (OS) and time to RN were assessed using Kaplan–Meier analysis. Logistic regression and Cox proportional hazards analyses were performed to identify predictors of radiation necrosis-free survival (RNFS) and RN risk. One-hundred thirty-seven patients with 1094 treated lesions over 296 SRS sessions were analyzed. Median follow-up was 9.8 months from SRS. Rate of RN was 27% of patients with median time to RN of 6 months. Median OS from SRS treatment was 16.9 months. RNFS at 6 months, 1 and 2 years was 92.7, 83.0, and 81.2%. Treatment with chemotherapy within 6 months of SRS was associated with worse RNFS at 1 year (78.4 vs. 87.5%, p = 0.017). On multivariate analysis, chemotherapy within 6 months and increased number of lesions treated were predictive of increased RN risk (HR 2.20, 95% CI 1.22–3.97, p = 0.009; HR 1.09, 95% CI 1.03–1.15, p = 0.002), whereas immunotherapy type and targeted therapy were not predictive. Median target volume of lesions that developed RN was greater than that of lesions that did not (p < 0.001). Concurrent treatment with chemotherapy, larger size and number of lesions treated were predictive of RN. Immunotherapy type and timing proximity to SRS were not associated with RN risk.
Similar content being viewed by others
References
Staudt M, Lasithiotakis K, Leiter U, Meier F, Eigentler T, Bamberg M et al (2010) Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer 102:1213–1218. doi:10.1038/sj.bjc.6605622
Chiarion-Sileni V, Guida M, Ridolfi L, Romanini A, Del Bianco P, Pigozzo J et al (2011) Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens. Br J Cancer 104:1816–1821. doi:10.1038/bjc.2011.178
Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG et al (2009) Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 10:1037–1044. doi:10.1016/S1470-2045(09)70263-3
Brown PD, Jaeckle K, Ballman KV, Farace E, Cerhan JH, Anderson SK et al (2016) Effect of radiosurgery alone vs. radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA 316:401–409. doi:10.1001/jama.2016.9839
Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB et al (2012) Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 13:1087–1095. doi:10.1016/S1470-2045(12)70431-X
Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M et al (2016) Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol 17:976–983. doi:10.1016/S1470-2045(16)30053-5
Queirolo P, Spagnolo F, Ascierto PA, Simeone E, Marchetti P, Scoppola A et al (2014) Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. J Neurooncol 118:109–116. doi:10.1007/s11060-014-1400-y
Kohutek ZA, Yamada Y, Chan TA, Brennan CW, Tabar V, Gutin PH et al (2015) Long-term risk of radionecrosis and imaging changes after stereotactic radiosurgery for brain metastases. J Neurooncol 125:149–156. doi:10.1007/s11060-015-1881-3
Colaco RJ, Martin P, Kluger HM, Yu JB, Chiang VL (2016) Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases? J Neurosurg 125:17–23. doi:10.3171/2015.6.JNS142763
Patel KR, Shoukat S, Oliver DE, Chowdhary M, Rizzo M, Lawson DH et al (2015) Ipilimumab and stereotactic radiosurgery versus stereotactic radiosurgery alone for newly diagnosed melanoma brain metastases. Am J Clin Oncol. doi:10.1097/COC.0000000000000199
Schoenfeld JD, Mahadevan A, Floyd SR, Dyer MA, Catalano PJ, Alexander BM et al (2015) Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review. J Immunother Cancer 3:50. doi:10.1186/s40425-015-0095-8
Du Four S, Hong A, Chan M, Charakidis M, Duerinck J, Wilgenhof S et al (2014) Symptomatic histologically proven necrosis of brain following stereotactic radiation and ipilimumab in six lesions in four melanoma patients. Case Rep Oncol Med 2014:417913. doi:10.1155/2014/417913
Shaw E, Scott C, Souhami L, Dinapoli R, Kline R, Loeffler J et al (2000) Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90–05. Int J Radiat Oncol Biol Phys 47:291–298
Voong KR, Farnia B, Wang Q, Luo D, McAleer MF, Rao G et al (2015) Gamma knife stereotactic radiosurgery in the treatment of brainstem metastases: the MD Anderson experience. Neuro-Oncol Pract 2:40–47. doi:10.1093/nop/npu032
Tazi K, Hathaway A, Chiuzan C, Shirai K (2015) Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery. Cancer Med 4:1–6. doi:10.1002/cam4.315
Kiess AP, Wolchok JD, Barker CA, Postow MA, Tabar V, Huse JT et al (2015) Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys 92:368–375. doi:10.1016/j.ijrobp.2015.01.004
Qian JM, Yu JB, Kluger HM, Chiang VLS (2016) Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery. Cancer 122:3051–3058. doi:10.1002/cncr.30138
Sneed PK, Mendez J, Vemer-van den Hoek JGM, Seymour ZA, Ma L, Molinaro AM et al (2015) Adverse radiation effect after stereotactic radiosurgery for brain metastases: incidence, time course, and risk factors. J Neurosurg 123:373–386. doi:10.3171/2014.10.JNS141610
Patel KR, Chowdhary M, Switchenko JM, Kudchadkar R, Lawson DH, Cassidy RJ et al (2016) BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis. Melanoma Res 26:387–394. doi:10.1097/CMR.0000000000000268
Patel BG, Ahmed KA, Johnstone PAS, Yu H-HM, Etame AB (2016) Initial experience with combined BRAF and MEK inhibition with stereotactic radiosurgery for BRAF mutant melanoma brain metastases. Melanoma Res 26:382–386. doi:10.1097/CMR.0000000000000250
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
No conflict of interest to disclose.
Rights and permissions
About this article
Cite this article
Fang, P., Jiang, W., Allen, P. et al. Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma. J Neurooncol 133, 595–602 (2017). https://doi.org/10.1007/s11060-017-2470-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-017-2470-4